Using period analysis to timely provide serial data on long-term survival for liver cancer patients from China

利用时期分析法及时提供中国肝癌患者长期生存的系列数据。

阅读:1

Abstract

BACKGROUND: Timely evaluation of long-term survival in liver cancer is essential for assessing early detection and screening efficacy. However, population-based survival data in China remain scarce, particularly for multi-decade analyses. This study systematically evaluated age-standardized 5-year relative survival (RS) in Taizhou, eastern China, and quantified temporal improvements from 2004 to 2023. METHODS: A retrospective cohort of 12,032 liver cancer patients diagnosed in Taizhou (2004-2023) was analyzed. Period analysis was used to compute age-standardized 5-, 10-, 15-, and 20-year RS rates, stratified by gender, age, and urban versus rural residence. Survival estimates were derived using actuarial methods with adjustments for competing mortality risks based on regional life tables. RESULTS: The 5-year RS for patients during 2019-2023 was 37.32%, significantly exceeding earlier periods (29.13% for 2014-2023, 23.00% for 2009-2023, and 5.56% for 2004-2023). Female patients consistently exhibited higher survival (39.23% vs. 37.26% for males), with a pronounced age gradient 5-year RS declined from 45.71% in patients <45 years to 26.05% in those >74 years. The urban-rural survival gap narrowed, with urban areas showing 37.83% versus 37.25% in rural areas (2019-2023). CONCLUSION: This study provides the most current population-based long-term RS data for liver cancer in Taizhou, offering a critical benchmark for enhancing early detection and screening programs in eastern China.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。